Get the Stockscreener App
2.61
0.76%
-0.02
After Hours:
2.62
0.01
+0.38%
Anixa Biosciences Inc stock is traded at $2.61, with a volume of 14,294.
It is down -0.76% in the last 24 hours and down -2.97% over the past month.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
See More
Previous Close:
$2.63
Open:
$2.67
24h Volume:
14,294
Relative Volume:
0.20
Market Cap:
$89.51M
Revenue:
-
Net Income/Loss:
$-12.48M
P/E Ratio:
-6.6923
EPS:
-0.39
Net Cash Flow:
$-7.93M
1W Performance:
-6.12%
1M Performance:
-2.97%
6M Performance:
-24.13%
1Y Performance:
-9.06%
1-Day Range:
$2.61
$2.75
1-Week Range:
$2.5301
$2.84
52-Week Range:
$2.07
$4.20
Anixa Biosciences Inc Stock (ANIX) Company Profile
Name
Anixa Biosciences Inc
Sector
Industry
Phone
408-708-9808
Address
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE
Compare ANIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANIX
Anixa Biosciences Inc
|
2.61 | 89.51M | 0 | -12.48M | -7.93M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-21-25 | Initiated | Maxim Group | Buy |
| Dec-23-22 | Initiated | Chardan Capital Markets | Buy |
| Apr-12-21 | Initiated | H.C. Wainwright | Buy |
Anixa Biosciences Inc Stock (ANIX) Latest News
Renaissance Technologies LLC Has $34,000 Stock Holdings in Anixa Biosciences, Inc. (NASDAQ:ANIX) - Defense World
Anixa Biosciences, Inc. (NASDAQ:ANIX) Shares Acquired by LPL Financial LLC - Defense World
Anixa Biosciences to Present at the H.C. Wainwright 3rd Annual B - GuruFocus
Anixa Biosciences to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20th - Nasdaq
Cancer Treatment Innovator Anixa Biosciences Takes Center Stage at Elite Nasdaq Conference - Stock Titan
ANIX Gets New Patent for Breast Cancer Vaccine Technology, Stock Up - MSN
ANIXAnixa Biosciences Inc Latest Stock News & Market Updates - Stock Titan
Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Presented at the Rivkin Center & American Association of Cancer Research (AACR) 14th Biennial Ovarian Cancer Research Symposium - Seeking Alpha
Anixa Biosciences (ANIX) Secures Patent to Advance CAR-T Cancer Therapy | ANIX Stock News - GuruFocus
Anixa Biosciences Receives Notice of Allowance from U.S. Patent - GuruFocus
Anixa Biosciences- Receives Notice Of Allowance For Car-T Technology Patent - marketscreener.com
Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for CAR-T Technology, Further Strengthening its Robust Intellectual Property Portfolio | ANIX Stock News - GuruFocus
Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for CAR-T Technology, Further Strengthening its Robust Intellectual Property Portfolio - Finansavisen
Indo-Asian News Service - Indo-Asian News Service (IANS)
Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Clinical Trial at the International Gynecologic Cancer Society 2024 Annual Meeting - marketscreener.com
Anixa Biosciences (NASDAQ:ANIX) Earns “Buy” Rating from D. Boral Capital - Defense World
Anixa Biosciences Stock Price, Quotes and Forecasts - Benzinga
Is AngioDynamics (ANGO) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Anixa gains US patent for breast cancer vaccine technology - Investing.com Australia
Anixa gains US patent for breast cancer vaccine technology By Investing.com - Investing.com Canada
Anixa Biosciences Shares Rise After Notice of Patent Allowance for Breast Cancer Vaccine - marketscreener.com
EXCLUSIVE: Anixa Biosciences Receives Key US Patent Nod For Breast Cancer Vaccine Patent - AOL.com
Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Covering Breast Cancer Vaccine Technology - BioSpace
Anixa Biosciences stock rises on patent win (ANIX:NASDAQ) - Seeking Alpha
Anixa Biosciences Receives Notice Of Allowance From U.S. Patent And Trademark Office - MarketScreener
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
EF Hutton Initiates Coverage of Anixa Biosciences (ANIX) with Buy Recommendation - MSN
Anixa Biosciences to Present at the Jones Las Vegas Healthcare and Technology Innovation Conference on April 9th - Quantisnow
Anixa Biosciences (NASDAQ:ANIX) Earns Buy Rating from D. Boral Capital - Defense World
What is HC Wainwright’s Forecast for ANIX Q1 Earnings? - Defense World
Anixa Biosciences’ (ANIX) Buy Rating Reaffirmed at HC Wainwright - Defense World
EXCLUSIVE: Anixa Biosciences Inks Letter of Intent with Austria-Based VERDI Solutions To Develop AI-Guided Personalized Cancer Vaccines - AOL.com
Anixa Enters Letter of Intent to Develop Verdi's AI-Guided Cancer Vaccines - MarketScreener
Anixa Biosciences Enters Letter of Intent with VERDI Solutions t - GuruFocus
VERDI Grants Anixa 6-month Right To Negotiate Transaction For Development Of VERDI's Cancer Vaccines - Nasdaq
Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines - Marketscreener.com
Anixa secures US patent for ovarian cancer vaccine tech By Investing.com - Investing.com Australia
EXCLUSIVE: Anixa Biosciences Poised To Receive US Patent For Ovarian Cancer Vaccine - AOL.com
Anixa secures US patent for ovarian cancer vaccine tech - Investing.com India
Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine - Marketscreener.com
Maxim Group Begins Coverage on Anixa Biosciences (NASDAQ:ANIX) - Defense World
Maxim Group Initiates Coverage of Anixa Biosciences (ANIX) with Buy Recommendation - MSN
Anixa Biosciences CEO to Present at the 2025 CAGLA NeauxCancer Conference on March 28th - Quantisnow
Anixa Biosciences Inc Stock (ANIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):